Heart failure with mid-range ejection fraction: are there clinical reasons in introduction of this new group as a distinct entity?

The article discusses the clinical expedience of isolating into a separate classification subgroup of patients with heart failure and a mid‑range ejection fraction (EF) of 40–49 %. Analysis of studies 2017–2018 focusing on the issue of patients with mid‑range LV EF showed that this subgroup is highly heterogenous and by some clinical and demographic parameters takes an intermediate position between heart failure (HF) patients with reduced (<40 %) and preserved (>50 %) LV EF. However, patients with mid‑range LV EF positively respond to beta‑blocker and RAAS inhibitor therapy, and their response is close to that of patients with reduced LV EF. This is a principal difference between patients with mid‑range and preserved LV EF who generally do not display any beneficial effect of such therapy. One of the major causes for such difference is a dissimilarity of HF etiology and, hence, pathogenesis in patients with reduced and mid‑range LV EF: primarily IHD (so‑called “ischemic” phenotype) in patients with reduced and mid‑range LV EF and non‑cardiac causes (“non‑ischemic” phenotype) in patients with preserved LV EF. Since the nonischemic phenotype is also rather common among patients with mid‑range LV EF a new HF classification should definitely indicate, in addition to LV EF, the clinical phenotype of disease, which is particularly important for patients with mid‑range LV EF of 40–49 %. Further studies should focus on variants of HF clinical phenotypes.

1. Ponikowski P, Voors AA, Anker SD, Bueno H, ClelandJ GF, Coats AJ S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2016;18(8):891-975. DOI: 10.1002/ejhf.592

2. Ageev F. T., Ovchinnikov A. G., Dreeva Z. V. What is new in the modern classification of heart failure? Heart failure with mid-range ejection fraction. Russian Heart Failure Journal. 2017;18(1):67-71.. DOI: 10.18087/rhfj.2017.1.2337

3. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction: Characteristics and outcomes in HFmrEF. European Journal of Heart Failure. 2017;19(12):1624-34. DOI: 10.1002/ejhf.945

4. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum: Candesartan across the ejection fraction spectrum. European Journal of Heart Failure. 2018;20(8):1230-9. DOI: 10.1002/ejhf.1149

5. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola V-P, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry: Analysis of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure. 2017;19(12):1574-85. DOI: 10.1002/ejhf.813

6. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. JACC: Heart Failure. 2016;4(6):464-72. DOI: 10.1016/j.jchf.2016.02.017

7. Lam CSP, Teng T-HK. Understanding Heart Failure With Mid-Range Ejection Fraction *. JACC: Heart Failure. 2016;4(6):473-6. DOI: 10.1016/j.jchf.2016.03.025

8. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study: Characterization of HFmrEF. European Journal of Heart Failure. 2017;19(10):1258-69. DOI: 10.1002/ejhf.807

9. Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goet-schalckx K, Pfister O, et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF): Heart failure with mid-range ejection fraction: a distinct clinical entity? European Journal of Heart Failure. 2017;19(12):1586-96. DOI: 10.1002/ejhf.798

10. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction: Heart failure with mid-range ejection fraction. European Journal of Heart Failure. 2017;19(12):1597-605. DOI: 10.1002/ejhf.879

11. Nauta JF, Hummel YM, van Melle JP, van der Meer P, Lam CSP, Pon-ikowski P, et al. What have we learned about heart failure with midrange ejection fraction one year after its introduction? European Journal of Heart Failure. 2017;19(12):1569-73. DOI: 10.1002/ejhf.1058

12. Lund LH, Vedin O, Savarese G. Is ejection fraction in heart failure a limitation or an opportunity?: Viewpoint. European Journal of Heart Failure. 2018;20(3):431-2. DOI: 10.1002/ejhf.1106

13. LuponJ, Bayes-Genis A. Left ventricular ejection fraction in heart failure: a clinician’s perspective about a dynamic and imperfect parameter, though still convenient and a cornerstone for patient classification and management: Editorial. European Journal of Heart Failure. 2018;20(3):433-5. DOI: 10.1002/ejhf.1116

14. Wolsk E, Claggett B, Kober L, Pocock S, Yusuf S, Swedberg K, et al. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure: Co-morbidity and cardiovascular outcomes in heart failure. European Journal of Heart Failure. 2018;20(3):504-10. DOI: 10.1002/ejhf.1073

15. Lund LH. Complex relationships between co-morbidity, outcomes, and treatment effect in heart failure: Editorial comment. European Journal ofHeart Failure. 2018;20(3):511-3. DOI: 10.1002/ejhf.1107

16. Mele D, Nardozza M, Ferrari R. Left ventricular ejection fraction and heart failure: an indissoluble marriage?: Editorial. European Journal of Heart Failure. 2018;20(3):427-30. DOI: 10.1002/ejhf.1071

17. Ovchinnikov A. G., Ozhereljeva M. V., Masenko V. P., Ageev F. T. Structure and function features and adverse prognostic factors of compensated hypertensive heart disease. Russian Heart Journal. 2017;16(3):185-96.. DOI: 10.18087/rhj.2017.3.2347